Why the study?
The impact of prosthesis-patient mismatch on clinical outcomes after TAVR may accumulate with extended follow-up and vary depending on whether measured or predicted indexed effective orifice area is used.
Does prosthesis-patient mismatch (PPM) impact long-term mortality in patients undergoing TAVR?
Does prosthesis-patient mismatch (PPM) impact long-term mortality in patients undergoing TAVR?
Prosthesis-patient mismatch following TAVR was not associated with an increased risk of death over long-term follow-up, and predicted EOAi yields lower estimates of PPM severity than measured EOAi.
PPM after TAVR was associated with lower long-term mortality; hypothesis-generating and should not change practice.
BACKGROUND: Both measured and predicted effective orifice area (EOA) indexed to the body surface area (EOAi) have been suggested to define prosthesis-patient mismatch (PPM) in patients undergoing transcatheter aortic valve replacement (TAVR). The impact of PPM on clinical outcomes may accumulate with extended follow-up and vary according to the definition used. AIMS: We aimed to investigate the long-term clinical impact of PPM in patients undergoing TAVR. METHODS: ). RESULTS: had a lower risk of 10-year all-cause mortality compared with those without PPM (adjusted hazard ratio: 0.73, 95% confidence interval: 0.55-0.96). CONCLUSIONS: The use of predicted versus measured EOAi results in a lower estimate of PPM severity. We observed no increased risk of death in patients with PPM over a median follow-up time of 429 days. CLINICALTRIALS: gov: NCT01368250.
No takes yet. Share an insight, caveat, or question.
Tomii et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: